Hemostasis and Tissue Sealing Agents market at a CAGR of 8.04% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Hemostasis and Tissue Sealing Agents Market”.

The Hemostasis and Tissue Sealing Agents Market is estimated to register a CAGR of 8.04% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the global Hemostasis and Tissue Sealing Agents market Johnson & Johnson (US), B Braun Medical Inc (Germany), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), Pfizer Inc (US), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India).

Hemostasis and Tissue Sealing Agents Market Highlights

The global Hemostasis and Tissue Sealing Agents market is accounted to register a CAGR of 8.04% during the forecast period and is estimated to reach USD 18.19 billion by 2032.

The global hemostasis and tissue sealing agents’ market is experiencing significant growth due to increasing surgical procedures, advancements in medical technology, and rising awareness about the benefits of these products. Hemostasis and tissue sealing agents play a crucial role in managing bleeding during surgeries, which is vital for ensuring patient safety and improving surgical outcomes. The market is driven by the growing prevalence of chronic diseases, an aging population, and the consequent rise in the number of surgical interventions. Additionally, technological advancements have led to the development of more effective and efficient hemostatic products, further propelling market growth.

Innovations such as fibrin sealants, gelatin-based products, and synthetic agents are expanding the applications of hemostatic and tissue sealing agents, making them indispensable in various surgical fields including cardiovascular, neurological, orthopedic, and general surgeries. The increasing preference for minimally invasive surgeries also boosts the demand for these agents, as they help reduce complications and improve recovery times. Furthermore, regulatory approvals and the introduction of new products by key market players are fostering a competitive environment that encourages continuous improvements and innovation

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hemostasis and Tissue Sealing Agents Market Research Report

Segment Analysis

The global Hemostasis and Tissue Sealing Agents market has been segmented based on Product, Material, Application, end user.

On the basis of Product, includes Topical Hemostat, and adhesive & tissue sealant. The Topical Hemostat segment is to hold the majority share in 2023 in the Global Hemostasis and Tissue Sealing Agents Market revenue. This is because of the rising number of surgical procedures and trauma cases, advancements in technology improving product efficacy, and the aging population increasing the need for surgeries. Additionally, the cost-effectiveness of topical hemostats, favorable regulatory approvals, and market expansion in emerging economies contribute significantly to their demand.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product therapy and services.

On the basis of the Material, the market is segmented into Chitosan-based Products and Mineral based Products. The Mineral based Products segment has dominated the market in 2023 and Chitosan-based Products is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to chitosan, derived from chitin found in shellfish, is biocompatible, biodegradable, and non-toxic, making it an attractive choice for medical and pharmaceutical applications. Its excellent hemostatic properties, which enable rapid blood clotting, are highly valued in wound care and surgical procedures.

On the basis of the end user, the market is segmented into Hospitals, Ambulatory Surgical Centers, and Research Institutes. The Hospitals segment has dominated the market in 2023 and Ambulatory Surgical Centers is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to Ambulatory Surgical Centers are cost-effective alternative to traditional hospital-based surgeries, providing significant savings for both patients and insurers. ASCs typically have lower overhead costs, which translates to reduced procedure costs which will drive the demand.

Regional Analysis

The global Hemostasis and Tissue Sealing Agents market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe Hemostasis and Tissue Sealing Agents market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Hemostasis and Tissue Sealing Agents market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s Hemostasis and Tissue Sealing Agents market comprises of Middle East, Africa, and Latin America.

Due to aging population, increasing prevalence of chronic diseases, and the continuous evolution of medical technology. With a focus on enhancing patient outcomes and reducing postoperative complications, the market has become a hub for research and development, resulting in the introduction of innovative products with superior efficacy. In 2019, Ethicon (US) introduced VISTASEAL Fibrin Sealant (Human) to manage bleeding during surgery. VISTASEAL Fibrin Sealant (Human) contains fibrinogen and thrombin, which are clotting proteins found in human plasma. When applied to the bleeding site, it forms a rapid, adherent, and durable clot. It has been demonstrated to sustain hemostasis (stoppage of bleeding), even in high-risk patients.

Moreover, the Europe market has been persistently growing owing to favorable health policies, and trend towards integrating health services in the European Hemostasis and Tissue Sealing Agents market.

Additionally, market factors, such as rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Hemostasis and Tissue Sealing Agents, and growing population in the Asia-Pacific region are driving the region’s growth.

Furthermore, the rest of the world's Hemostasis and Tissue Sealing Agents market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of the Hemostasis and Tissue Sealing Agents market in the region has experienced increasing number of surgical procedures and advancements in healthcare infrastructure. Key factors driving this market include the rising prevalence of chronic diseases necessitating surgical interventions and the growing adoption of advanced medical technologies are expected to propel the Hemostasis and Tissue Sealing Agents market growth in the region.

Key Findings of the Study

• The global healthcare counseling market is expected to reach USD 18.19 billion by 2032, at a CAGR of 8.04% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the rising spending in healthcare, quickly evolving healthcare, and growing population in the Asia-Pacific region.


• Based on application, the General Surgery segment was attributed to holding the largest market in 2022, with an approximate market share of 35–40%.


• Johnson & Johnson (US), B Braun Medical Inc (Germany), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), Pfizer Inc (US), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India) are the key market players.